News

Austria currently lacks a formally endorsed national health economic evaluation guideline (HEEG) with detailed methodological specifications, which hinders the broader application of health economic evidence in reimbursement decisions. This review systematically examined mandatory HEEGs from high-income countries to identify common standards for conducting health economic evaluations, synthesising findings into a structured overview of methodological convergence and divergence at the international level. The results are intended to support Austrian policymakersand HTA stakeholders in developing a nationally tailored, methodologically robust guideline applicable across a wide range of healthcare decision-making contexts.

Anxiety and depressive disorders account for a significant proportion of the global mental health burden. Treatment challenges in antidepressant therapy have stimulated interest in adjunctive nutritional interventions, such as B vitamins, due to their role in neurobiological processes relevant to mood regulation. However, existing systematic reviews have not focused specifically on adjunctive regimens combining multiple B vitamins with antidepressants. Consequently, this systematic review aimed to evaluate the efficacy and safety of combining a vitamin B complex (?2 B vitamins) with antidepressant medication to improve symptom severity in depression and anxiety.

High-throughput sequencing technologies enable the simultaneous analysis of multiple genes or the entire genome in a single run and are increasingly used for the detection of clinically relevant genetic alterations. This assessment evaluated the clinical effectiveness, safety, and economic, organisational, and ethical aspects of high-throughput sequencing for the detection of PIK3CA, AKT1, PTEN, and ESR1 genetic alterations in breast cancer diagnostics. The target population comprises adults diagnosed with HR+/HER2–, locally advanced or metastatic breast cancer.

Carrier screening is a screening strategy designed to identify asymptomatic individuals who carry pathogenic variants for autosomal recessive and X-linked hereditary conditions. This assessment evaluated the clinical effectiveness, safety, economic, organisational, and ethical aspects of different carrier screening strategies: universal versus risk-based approaches and single-disease panels versus expanded carrier screening (ECS). The target population comprised reproductive-age individuals and pregnant women.

Technological advances in genetic testing expand clinical care, yet necessitate evidence-based decision-making. This scoping review establishes the methodological basis for topic prioritisation in Austria by mapping application fields and analysing international evidence-based reimbursement processes. This report is the first part within the project Genetic Testing in Austria and informs topic prioritisation for two assessments in the field.

Reliable cost data is the cornerstone of informed healthcare decision-making. This project analyses international guidelines to map best practices in costing processes. On this basis, well-founded recommendations for the evaluation of health care services can be derived, promoting comparability and transparency.

Polypharmacy poses major challenges to medication safety, particularly for older people with multimorbidity. This report summarises the current evidence on the effectiveness, safety, organisational aspects and costs of structured medication reviews (SMRs). It also compares implementation models across selected European countries.

Lysosomal storage diseases such as Pompe disease and mucopolysaccharidoses (MPS I, II, IVA) are rare inherited metabolic disorders leading to multi-organ involvement. This systematic review assessed the long-term effectiveness and safety of enzyme replacement therapies (ERTs) currently approved for these conditions (alglucosidase alfa, avalglucosidase alfa, laronidase, idursulfase, elosulfase alfa). Due to predominantly small, uncontrolled studies, heterogeneous study designs, methodological limitations, and a lack of comparability between studies, the overall certainty of the identified evidence is very low. Consequently, a reliable and definitive assessment of long-term effectiveness and safety is currently not possible for the ERTs evaluated. The use of ERT therefore requires careful patient selection, structured monitoring and documentation with the collection of standardized endpoints, as well as predefined criteria for continuation or discontinuation of therapy.